These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22793527)

  • 1. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.
    Eisner MD; Zazzali JL; Miller MK; Bradley MS; Schatz M
    J Asthma; 2012 Aug; 49(6):642-8. PubMed ID: 22793527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
    Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
    J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab versus 'usual care': results from a naturalistic longitudinal study in routine care.
    Wittchen HU; Mühlig S; Klotsche J; Buhl R; Kardos P; Ritz T; Riedel O
    Int Arch Allergy Immunol; 2012; 159(1):83-93. PubMed ID: 22573022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
    Bardelas J; Figliomeni M; Kianifard F; Meng X
    J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between consistent omalizumab treatment and asthma control.
    Lafeuille MH; Gravel J; Zhang J; Gorsh B; Figliomeni M; Lefebvre P
    J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D; Talker O; Metabichek A; Yaakovi I
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
    Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma.
    Janson SL; Solari PG; Trzaskoma B; Chen H; Haselkorn T; Zazzali JL
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):516-21. PubMed ID: 26021894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the Asthma Control Composite outcome measure to predict omalizumab response.
    Harris JM; Wong DA; Kapp AV
    Ann Allergy Asthma Immunol; 2011 Sep; 107(3):273-80.e1. PubMed ID: 21875548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
    Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
    Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics of patients enrolled in EXCELS: a cohort study.
    Long AA; Fish JE; Rahmaoui A; Miller MK; Bradley MS; Taki HN; Demeo AN; Tilles SA; Szefler SJ
    Ann Allergy Asthma Immunol; 2009 Sep; 103(3):212-9. PubMed ID: 19788018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
    Menzella F; Facciolongo N; Piro R; Formisano D; Roggeri A; Simonazzi A; Castagnetti C; Carbonelli C; Zucchi L
    Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.